查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1590837

青光眼治療市場：依適應症、類型、銷售管道- 2025-2030 年全球預測

Glaucoma Treatment Market by Indication (Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma), Type (Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年青光眼治療市場價值為67.3億美元，預計到2024年將達到73.1億美元，複合年成長率為8.94%，到2030年將達到122.7億美元。

青光眼治療市場對於控制不可逆性失明的主要原因非常重要，包括主要旨在降低眼壓和保留視神經功能的各種治療方法和設備。隨著青光眼盛行率的不斷上升和世界人口的老化，對有效治療解決方案的需求不斷擴大。市場應用範圍涵蓋藥物治療（琴酒類似物、 BETA阻斷劑、α-促效劑、碳酸酐酶抑制劑）、雷射治療、手術介入（小梁切除術、引流植入植入），最終使用者主要包括眼科診所、醫院、研究機構。市場成長的推動因素包括給藥系統技術創新的進步、早期診斷意識的提高以及人工智慧的引入以實現更好的疾病管理。然而，高昂的治療成本和潛在的副作用帶來了挑戰，需要提高患者對治療方法的依從性。

主要市場統計
基準年[2023] 67.3億美元
預測年份 [2024] 73.1億美元
預測年份 [2030] 122.7億美元
複合年成長率（%） 8.94%

新型療法和個人化醫療方法的開發存在著巨大的商機，這與業界向精準醫療的轉變一致。公司可以探索與生物技術領域的合作夥伴關係，並投資於緩釋性藥物配方和微創設備的臨床試驗。也就是說，監管障礙和冗長的核准流程可能會限制市場動態，凸顯了簡化核准工作流程的必要性。非侵入性診斷和治療監測工具的創新具有巨大的成長潛力。此外，透過擴大醫療基礎設施進入新興市場可能是一項盈利的投資。儘管有這些機遇，但智慧財產權問題和發展中地區准入有限等挑戰仍然存在，需要進行策略調整。了解市場競爭和技術進步的步伐非常重要。因此，企業必須培育強力的研發舉措，並考慮與學術機構合作進行尖端研究創新，以便在這個不斷變化的環境中保持領先地位。這種多方面的方法不僅會加強我們的市場地位，還會提高治療效率和患者的治療效果。

市場動態：揭示快速發展的青光眼治療市場的關鍵市場洞察

供需的動態交互作用正在改變青光眼治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 隨著青光眼發生率的增加，老年人口也增加
    • 政府和製藥界不斷舉措提高對青光眼的認知
    • 人口中智慧型設備的使用和螢幕時間可能會增加
  • 市場限制因素
    • 欠低度開發國家缺乏早期診斷
  • 市場機會
    • 眼藥水技術不斷進步
    • 活性化製藥和生技公司的研發活動（青光眼治療）
  • 市場挑戰
    • 對藥品召回的擔憂

波特五力：駕馭青光眼治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解青光眼治療市場的外在影響

外部宏觀環境因素在塑造青光眼治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解青光眼治療市場的競爭狀況

青光眼治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣青光眼治療市場供應商的績效評估

FPNV定位矩陣是評估青光眼治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製青光眼治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對青光眼治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加，青光眼發生率上升
      • 政府和製藥組織加大力度提高對青光眼的認知
      • 智慧型裝置的使用和螢幕時間可能會增加
    • 抑制因素
      • 開發中國家缺乏早期診斷
    • 機會
      • 眼藥水的創新仍在持續
      • 製藥和醫療產業的研發活動增加

青光眼治療生技公司

    • 任務
      • 對藥品召回的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章青光眼治療市場：依適應症分類

  • 隅角閉鎖性青光眼
  • 先天性青光眼
  • 開放性青光眼
  • 續發性青光眼

第7章青光眼治療市場：依類型

  • α促效劑
  • BETA受體阻斷劑
  • 碳酸酐酶抑制劑
  • 膽鹼能的
  • 伴隨藥物
  • 前列腺素琴酒

第8章青光眼治療市場：依銷售管道

  • 醫院藥房
  • 網上銷售
  • 零售藥房

第9章美洲青光眼治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太青光眼治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲青光眼治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Accutome, Inc.
  • Akorn Operating Company LLC
  • Alcon Vision LLC
  • Amorphex Therapeutics LLC
  • ASICO LLC
  • Bausch+Lomb Corporation
  • Bayer AG
  • Carl Zeiss Meditec AG
  • Fera Pharmaceuticals, LLC
  • Glaukos Corporation
  • Inotek Pharmaceuticals
  • Lumenis Be Ltd.
  • Merck & Co, Inc.
  • Mobius Therapeutics, LLC
  • NIDEK CO., LTD.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Perrigo Company PLC
  • Pfizer, Inc.
  • Quantel Medical
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Topcon Corporation
Product Code: MRR-430D3EB72947

The Glaucoma Treatment Market was valued at USD 6.73 billion in 2023, expected to reach USD 7.31 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 12.27 billion by 2030.

The glaucoma treatment market, crucial for managing a leading cause of irreversible blindness, predominantly encompasses various therapies and devices aimed at reducing intraocular pressure and preserving optic nerve function. With the rising prevalence of glaucoma and an aging global population, the necessity for effective treatment solutions is expanding. The market's application scope spans medication (prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors), laser therapy, and surgical interventions (trabeculectomy and drainage implants), while end-users primarily include ophthalmology clinics, hospitals, and research institutes. Market growth is fueled by advancing innovations in drug delivery systems, increased awareness of early diagnosis, and the incorporation of artificial intelligence for better disease management. However, high treatment costs and potential side effects pose challenges, alongside the need for improved patient adherence to treatment regimens.

KEY MARKET STATISTICS
Base Year [2023] USD 6.73 billion
Estimated Year [2024] USD 7.31 billion
Forecast Year [2030] USD 12.27 billion
CAGR (%) 8.94%

There are significant opportunities in the development of novel therapeutic agents and personalized medicine approaches, which align with the industry's shift towards precision treatment. Companies can explore partnerships within the biotech sector and invest in clinical trials focusing on sustained-release drug formulations and minimally invasive devices. Nevertheless, regulatory hurdles and lengthy approval processes can constrain market dynamics, emphasizing the need for streamlined approval workflows. Innovating within non-invasive diagnosis and treatment monitoring tools presents substantial growth potential. Further, tapping into emerging markets with expanding healthcare infrastructure offers profitable ventures. Despite these opportunities, persistent challenges such as intellectual property issues and limited accessibility in developing regions require strategic adaptation. Comprehending the competitive nature of the market and the pace of technological advancements is critical. Consequently, businesses must foster robust R&D initiatives to stay ahead in this constantly evolving landscape and consider collaborations with academic institutions for cutting-edge research innovations. This multi-faceted approach not only fortifies market position but also enhances treatment efficiency and patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Treatment Market

The Glaucoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population coupled with rising incidences of glaucoma
    • Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
    • Potential rise in the use of smart gadgets and screen time among the population
  • Market Restraints
    • Lack of early diagnosis in underdeveloped economies
  • Market Opportunities
    • Ongoing technological advancement with eye drops
    • Increasing research and development activities from pharmaceutical and biotechnological companies for glaucoma treatment
  • Market Challenges
    • Concerns associated with drug recalls

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Treatment Market

A detailed market share analysis in the Glaucoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Treatment Market

A strategic analysis of the Glaucoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accutome, Inc., Akorn Operating Company LLC, Alcon Vision LLC, Amorphex Therapeutics LLC, ASICO LLC, Bausch + Lomb Corporation, Bayer AG, Carl Zeiss Meditec AG, Fera Pharmaceuticals, LLC, Glaukos Corporation, Inotek Pharmaceuticals, Lumenis Be Ltd., Merck & Co, Inc., Mobius Therapeutics, LLC, NIDEK CO., LTD., Novartis AG, Ocular Therapeutix, Inc., Perrigo Company PLC, Pfizer, Inc., Quantel Medical, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma, and Secondary Glaucoma.
  • Based on Type, market is studied across Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, Combined Medications, and Prostaglandin Analogs.
  • Based on Sales Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population coupled with rising incidences of glaucoma
      • 5.1.1.2. Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
      • 5.1.1.3. Potential rise in the use of smart gadgets and screen time among the population
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of early diagnosis in underdeveloped economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancement with eye drops
      • 5.1.3.2. Increasing research and development activities from pharmaceutical and

biotechnological companies for glaucoma treatment

    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with drug recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glaucoma Treatment Market, by Indication

  • 6.1. Introduction
  • 6.2. Angle Closure Glaucoma
  • 6.3. Congenital Glaucoma
  • 6.4. Open Angle Glaucoma
  • 6.5. Secondary Glaucoma

7. Glaucoma Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Alpha Agonist
  • 7.3. Beta Blockers
  • 7.4. Carbonic Anhydrase Inhibitors
  • 7.5. Cholinergic
  • 7.6. Combined Medications
  • 7.7. Prostaglandin Analogs

8. Glaucoma Treatment Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Sales
  • 8.4. Retail Pharmacies

9. Americas Glaucoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Glaucoma Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Glaucoma Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Accutome, Inc.
  • 3. Akorn Operating Company LLC
  • 4. Alcon Vision LLC
  • 5. Amorphex Therapeutics LLC
  • 6. ASICO LLC
  • 7. Bausch + Lomb Corporation
  • 8. Bayer AG
  • 9. Carl Zeiss Meditec AG
  • 10. Fera Pharmaceuticals, LLC
  • 11. Glaukos Corporation
  • 12. Inotek Pharmaceuticals
  • 13. Lumenis Be Ltd.
  • 14. Merck & Co, Inc.
  • 15. Mobius Therapeutics, LLC
  • 16. NIDEK CO., LTD.
  • 17. Novartis AG
  • 18. Ocular Therapeutix, Inc.
  • 19. Perrigo Company PLC
  • 20. Pfizer, Inc.
  • 21. Quantel Medical
  • 22. Santen Pharmaceutical Co., Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. GLAUCOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLAUCOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLAUCOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023